Aim: Branched-chain amino acids (BCAA) are valuable in the treatment of liver cirrhosis because they increase serum albumin levels. Poor adherence to BCAA may adversely affect prognosis, but little is known about factors predicting adherence. We undertook a survey of patients prescribed BCAA for the treatment of cirrhosis.
INTRODUCTION
L IVER CIRRHOSIS CAN be the end stage of chronic disease processes that cause ongoing and progressive hepatic injury. The quality of life of patients with liver cirrhosis is also reduced in decompensated stages of disease, with symptoms including fatigue, edema, ascites, hepatic encephalopathy, and cramp. 1 In Japan, approximately 30 000 people died from liver cancer in 2014, 2 and most of these were considered to have liver cirrhosis. [3] [4] [5] Because the prognosis of patients with decompensated cirrhosis is related to hypoalbuminemia in many cases, 6 numerous interventions have been proposed to improve albumin levels, including branched-chain amino acid (BCAA) granules. 7, 8 Several clinical trials have shown that treatment with BCAA granules increases serum albumin levels in patients with liver cirrhosis. [9] [10] [11] [12] Branched-chain amino acid granules have been shown to reduce the development of cirrhosis-related complications such as infection and kidney failure. 13 Based on the clinical efficacy of BCAA granules, international and Japanese guidelines for the management of cirrhosis recommend the use of BCAA granules as nutritional therapy in these patients. 14, 15 Specifically, in Japan, BCAA granule prescriptions are covered by the National Health Insurance system in patients with hypoalbuminemia (≤ 3.5 g/dL serum albumin) who have abdominal dropsy, edema, or hepatic encephalopathy, and in patients with a history of decompensated cirrhosis, and hypoalbuminemia despite sufficient dietary albumin intake.
Clinical trials have also reported that BCAA granules are effective for preventing the development of hepatic carcinoma, and their use has been shown to improve the prognosis of patients with cirrhosis. 11, [16] [17] [18] Many patients with hepatitis are aged and may have been taking BCAA for a long time. As a consequence, their adherence to medication may progressively decrease. Notably, Takaguchi et al. reported that adherence to BCAA granules affected the prognosis of patients with liver cirrhosis. 12 The investigators found that patients with good adherence (defined as administration of "nearly all" prescribed doses) were less likely to require hospitalization due to progression of hepatic failure than patients with poor adherence (defined as administration of "approximately half" or "less than half" of the prescribed doses).
To our knowledge, however, no other studies have examined the subjective factors that might influence the level of adherence to BCAA granules among patients with liver cirrhosis. Therefore, it is important to obtain further insight into the adherence to BCAA granules in clinical settings and to examine the subjective factors that might influence adherence. Accordingly, the aim of this study was to identify the subjective factors that might affect adherence to BCAA granules in patients with liver cirrhosis.
This study was jointly undertaken by the Saga Medical School Faculty of Medicine, Saga University and Saga Pharmaceutical Association (all in Saga, Japan).
METHODS

Patient selection
T HIS SURVEY WAS carried out by 511 pharmacies in Saga Prefecture, Japan, which were asked to take part in this study. All patients with liver cirrhosis who fulfilled the Japanese National Health Insurance system criteria for receiving BCAA granules who visited these pharmacies to collect their prescribed BCAA granules from 1 March 2014 to 31 May 2014 were sequentially enrolled, regardless from which clinic or hospital the patient had received the prescription from.
Ethics
The survey was carried out on a face-to-face basis after gaining informed consent from each patient for Saga prefecture liver disease database project. This study was undertaken in accordance with the Declaration of Helsinki principles, and was approved by the ethics committee of Saga University (IRB No. 2014-10-10).
Granule formulations
As part of the survey, patients were asked which of nine formulations of BCAA granules they had been prescribed (see Fig. S1 ). All nine formulations included the same composition and dosage of three amino acids (L-isoleucine 952 mg, L-leucine 1904 mg, and L-valine 1144 mg). The specific formulations and pack amounts were: LIVACT Granules (4.15 g pack; Ajinomoto Pharmaceuticals Co., Ltd., Tokyo, Japan); Hepaact Combination Granules (4.5 g pack; Toa Pharmaceuticals Co., Ltd., Toyama, Japan); BRANUTE Combination Granules (4.73 g pack; Nihon Pharmaceutical Co., Ltd., Tokyo, Japan); Aminovact Combination Granules (4.74 g pack; Nichi-Iko Pharmaceutical Co., Ltd., Toyama, Japan); Aminomylan Combination Granules (4.74 g pack; Mylan Pharmaceutical Co., Ltd., Amsterdam, The Netherlands); COVENEAL Combination Granules (4.74 g pack; Yoshindo Inc., Toyama, Japan); LICKLE Combination Granules (4.74 g pack; Sawai Pharmaceutical Co., Ltd., Osaka, Japan); LIVEREVAN Combination Granules (4.74 g pack; Medisa Shinyaku Inc., Osaka, Japan); and LEOVACTON Combination Granules (4.74 g pack; Choseido Pharmaceutical Co., Ltd., Tokushima, Japan).
Questionnaires and survey
The survey period was from 1 March 2014 to 31 May 2014. The survey consisted of structured interviews with patients prescribed BCAA granules, or the patient's representative (e.g., family member or caregiver). It included information about the prescribed medication, the patient's background characteristics, adherence to the medication, factors affecting adherence, degree of understanding about the effectiveness of BCAA granules and their importance, and the respondent's impression of the patient's main educator. The questionnaires used and the design of the survey are shown in Figures S1 and S2 , respectively. The first half of the questionnaire was completed by the pharmacist using the patient's records, and the second half was completed during the face-to-face survey.
If the respondent did not know the answer to a question, the response was recorded as "unknown". If the respondent declined to answer a question for any reason, the response was recorded as "unanswered". If the respondent did not know the answer because the interview was carried out at the time of the patient's first prescription, the response was recorded as "first prescription".
Statistical methods and definitions of adherence
Adherence to the medication was determined based on patient answers to questions 13 and 16 of the survey (Fig. S1 ). In the first instance, patients with "good adherence" were defined as those who said "yes" to question 13 of the survey ("Do you take your medication appropriately?"). Although not listed in the questionnaire, during this question patients were advised that taking their medication accurately "not all the time", "most of the time", or "half or less of the time" would be counted as a "no" to question 13. However, if a patient or their representative subsequently answered "yes" to components of question 16 (e.g., "forget to take medication"), even if they answered "yes" to question 13, they were defined as having "poor adherence". "Good" adherence was therefore defined as a "yes" answer to question 13 and a "no" answer to all of question 16. For analyses of adherence, we excluded the respondents if their responses were "first prescription" or "unknown". Results are presented as cross tables and were analyzed using Pearson's χ 2 -test. Statistical significance was defined as P < 0.05. SPSS Statistics version 22 (IBM, Armonk, NY, USA) was used for all analyses.
RESULTS
Patients
O NE HUNDRED AND seven out of 511 (20.9%) pharmacies and 253 respondents (patients or their representatives) participated in the study and completed the interview. The respondent was the patient in 155 cases, a family member in 41 cases, a caregiver in 9 cases, and anonymous in 48 cases. The patients comprised 135 men and 114 women. Gender was not specified for four patients. The characteristics of the patients, including age, living and working status, duration of BCAA prescription, and concomitant medications are shown in Table 1 .
Most patients were ≥60 years old, lived with others, and were not working. The mean ± standard deviation number of prescribed medications was 7.1 ± 3.3 (range, 1-17).
Prescription of BCAA granules
Details about the prescription of BCAA granules are given in Table 2 .
The prescriptions for BCAA granules currently held by patients ranged from ≤13 days to ≥85 months. The overall length of treatment with BCAA granules ranged from ≤3 months to >3 years. The majority of patients were taking three prescription packs per day.
Overall, 106 patients were reported to have subjective symptoms at the time of this survey, and 135 patients had no problems. Of 106 patients with subjective symptoms, the symptoms were fatigue in 51, edema in 44, cramp in 41, bowel distension in 14, and other symptoms in 4. Forty-one patients had multiple symptoms. Overall, 192 respondents reported that the administration of the medication was supervised by the patient him/herself.
Two hundred of the respondents (79.1%) reported that the patient took the medication appropriately (answered "yes" to question 13), and 32 reported that the medication was not taken appropriately. Eighteen respondents left the question unanswered. The survey was conducted at the first prescription for three patients.
Sixty-nine patients "forgot to take medication", and 42 of these 69 respondents reported that the patient forgot to take the medication in the afternoon. Adherence to branched-chain amino acid granules E171 Hepatology Research 2017; 47: E169-E177 2) †Percentages for this question have been calculated using the number of patients answering 'yes' to the previous question, and not the total number of patients, as the denominator. All other percentages are calculated using the total number of patients (n = 253) as the denominator.
Seventy-nine respondents reported that it was unpleasant to take the medication. Of these, 45 reported it was unpleasant to administer the medication because of its volume and 40 of the respondents stated that the taste of BCAA was unpleasant. Specifically, the formulation was reported to be granular and tasted bitter.
Other reasons for not taking the medication included weariness with the medication, patients felt it was unnecessary to take the medication, concern about side-effects, and concern about its cost, which were reported by 53, 39, 19, and 18 respondents, respectively.
Adherence to BCAA granules and associated factors
The overall adherence rate, which was calculated as the number of patients with good adherence (based on combined answers to questions 13 and 16)/total number of patients, was 63.2% (160/253). The factors associated with adherence to BCAA granules are presented in Table 3 . The adherence rate was not significantly different among subgroups of patients divided by sex, age, working status, number of prescriptions, duration of prescription, period of overall prescription (period from the first prescription), number of packs per day, or side-effects after taking the medication.
The adherence rates tended to be higher among inpatients and patients whose medications were managed by someone else (P = 0.054). However, the adherence rates tended to be lower for patients who did not feel the need for the medication (P = 0.063), those who were concerned about side-effects (P = 0.064), and those who were worried about the cost of medication (P = 0.055).
The adherence rate was also significantly correlated with weariness with taking the medication (P < 0.001) and the unpleasantness of taking the medication (P = 0.023). Indeed, taste and volume were the two significant contributors to the difficulty in administering the medication.
All 253 respondents answered at least one question regarding their knowledge about the efficacy of BCAA granules; multiple responses were allowed for these questions. Thirty-five respondents did not answer every section. Overall, 95, 55, 58, 36, 48, and 20 respondents reportedly knew that BCAA granules "prevent liver cancer incidence", "prolong life expectancy", "increase albumin levels", "decrease cramp", "decrease fatigue", and "stabilize blood sugar", respectively. Of these, 77, 44, 34, 15, 32, and 10 respondents, respectively, kept these facts in their mind. In addition, 79, 20, 29, 2, 14, and 2 respondents, respectively, believed that the specific fact was the most important effect of BCAA granules (one response only) (Fig. 1) . All 253 respondents answered questions about the patients educator (i.e., the person who provided the patient/respondent with information about the drug). Multiple responses were allowed. Fifty-five respondents did not complete all of the questions. The patient's educator was reported to be a general practitioner (GP), certified hepatologist, pharmacist, national registered dietitian, hepatitis coordinator, public health nurse, nurse, and acquaintance/family by 141, 72, 68, 9, 4, 1, 13, and 7 respondents, respectively. Of these, 112, 53, 34, 3, 1, 1, 5, and 4 respondents, respectively, remembered receiving information from these educators. Notably, the most influential educators were reported to be GPs, certified hepatologists, and pharmacists by 110, 44, and 11 respondents, respectively (Fig. 2) .
DISCUSSION
T HIS WAS THE first study to investigate the subjective factors affecting adherence to BCAA granules among decompensated liver cirrhosis patients with hypoalbuminemia. The study also examined the respondent's recognition and interpretation of the intended therapeutic effects of BCAA granules and the influence of different clinical educators regarding BCAA efficacy.
Prior reports on medication adherence in other chronic diseases, such as diabetes, have shown that various factors affect adherence. Fürthauer et al. found that patients with diabetes with low adherence may not take their medication as prescribed because they accept their symptoms as normal, or may not even notice them. 19 In a review, Lerman cited other possible reasons for low adherence among diabetic patients including lack of social support, poor knowledge about the implications of disease and of not taking medication, substance abuse, and even forgetfulness. 20 An interview survey undertaken among patients with non-insulin-dependent diabetes found that most patients believed their condition to be serious and with complications, but they were able to reconcile this view with flexible adherence to medical advice. 21 Taken together, these findings emphasize the complex nature of patient adherence to medications, even in cases of serious chronic disease.
The World Health Organization reported that the following three factors were mandatory to ensure adherence to medication: sharing of the treatment policy between patients and medical staff; participation of the patient in the decision-making process regarding their medication; and good communication between the patient and medical staff. The World Health Organization also noted that adherence could decrease if long-term treatment was necessary. 22 Other studies have also revealed that patient understanding and awareness of the risks of a disease were important predictors of adherence. 23, 24 Social support from family and friends was also reported to be important in improving long-term adherence to medications, together with counseling, reminders about appointments and adherence, and providing recognition or rewards to the patient for adhering to the prescribed regimen. 25 Furthermore, better understanding of the need for taking the prescribed medication was reported to improve adherence. 26 It was reported that the most important clinical effect of BCAA granules was the improvement in serum albumin, [9] [10] [11] and that this improvement is correlated with treatment adherence. 12 Unfortunately, serum albumin was not measured as part of our survey. Therefore, we were unable to examine whether the respondent-reported adherence was correlated with the patient's serum albumin concentrations.
In the present study, 160/232 respondents (69.0%) reported that the patient took the medication appropriately and remembered to administer it; the other 72 patients (31.0%) needed to improve their adherence. Forgetting to take a prescribed medicine is a common problem that affects medication adherence in most clinical settings. 27, 28 Therefore, it is important to address this issue in clinical practice.
The respondents were also asked about the unpleasantness of administering the medication, and approximately half of them stated that the taste or volume was unpleasant. Consequently, the development of new drugs or formulations using alternative excipients with better taste/texture, for example, may solve these issues and improve adherence to oral medications. 29 Regarding the understanding of efficacy of BCAA granules, more respondents (95; 37.5%) knew about the effect of BCAA on preventing liver cancer than knew about the improvement of serum albumin, despite the latter being a well-researched effect of BCAA granules. Moreover, 79 (31.2%) of the respondents reported that preventing liver cancer was the most important feature of this drug. Conversely, 58 respondents (22.9%) knew that the improvement in serum albumin was the original effect of BCAA, and 29 (11.5%) considered it was the most important feature.
Several studies have described beneficial effects of BCAA granules in terms of preventing the development liver cancer. 11, 17 It is possible that healthcare educators believed that this finding was most relevant to their patients, and therefore focused their explanations on this point. The results of the present study show that the respondents were generally influenced more by the possibility of preventing liver cancer and prolonging life expectancy than by the improvement in the levels of serum albumin. Therefore, the respondents were probably more aware of and even expecting these outcomes, which might have contributed to adherence. However, 35 respondents (13.8%) stated that they had never heard of these effects.
In this study, the relationship between understanding the effects of BCAA and adherence remains unclear. However, it may be possible to increase adherence by ensuring the patient, caregiver, or family member better understands the effects of BCAA. This is particularly important for individuals who believe BCAA granules are inconvenient to administer.
Most of the educators were GPs, followed by certified hepatologists and pharmacists. It is notable that GPs, followed by certified hepatologists and pharmacists, had the greatest impression on the respondent's awareness of BCAA. These results suggest that GPs have the greatest impact in terms of explaining the effects of BCAA granules. Although pharmacists play important roles in terms of preparing the prescriptions and explaining the prescribed drug's effects and terminology, they made weaker impressions on the respondents. Nevertheless, pharmacists may contribute more to the patient's understanding of the medication if they communicated more about the desired effects of, and reasons for, taking the prescribed medication.
Considering that weariness was associated with reduced adherence, healthcare professionals should repeatedly explain that it is important to take the medication regularly. Additionally, pharmacists should ask patients if they feel weariness, and ascertain their willingness to take BCAA granules. Ideally, pharmacists could increase their efforts to help prevent weariness.
Our study had several major limitations. First, the questionnaire consisted of closed questions and was delivered in a face-to-face method, which may have influenced the respondent's choices. In particular, the respondents may have chosen responses that they thought would be more favorable to the interviewer by stating their adherence was greater than it actually was. Unfortunately, we did not include an objective indicator of adherence to BCAA granules such as the BCAA/tyrosine ratio, which was used in the study by Takaguchi et al., 12 to examine the reliability of the responses. Second, the questions focused on a particular moment in time, and the respondent's answers may change over time. Third, the questions were answered by the patients themselves or by the patients' representatives. It is possible that recall bias may exist or that the representative "guessed" or was unaware of the most relevant answer to each question.
In conclusion, we found that reduced adherence to BCAA granules was correlated with weariness with taking the medication and the unpleasantness of the medication itself, specifically, the taste, texture, and volume. Changes in the volume and taste of BCAA granules may improve convenience and adherence. In addition, healthcare professionals need to pay attention to the weariness of patients on long-term medications and address this factor in order to improve medication adherence. Patient education from GPs and hepatologists combined with adherence counseling from pharmacists may help improve adherence.
